Insider Transactions in Q2 2023 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2023
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,655
-2.81%
|
$23,170
$14.4 P/Share
|
|
Jun 16
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,238
-2.08%
|
$17,332
$14.4 P/Share
|
|
Jun 16
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,655
-2.81%
|
$23,170
$14.4 P/Share
|
|
Jun 16
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,655
-1.85%
|
$23,170
$14.4 P/Share
|
|
Jun 16
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,238
-2.75%
|
$17,332
$14.4 P/Share
|
|
Jun 08
2023
|
Franklin Stuart Friedman |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$130,000
$13.88 P/Share
|
|
May 10
2023
|
Dennis Leo Walsh |
BUY
Open market or private purchase
|
Direct |
11,000
+50.0%
|
$143,000
$13.86 P/Share
|